PMGC Holdings Inc. Announces License Amendment and Share Increase

What Happened

• PMGC Holdings Inc. (ticker ELAB) filed an 8-K disclosing that its wholly owned subsidiary NorthStrive Biosciences entered a First Amendment to the April 9, 2025 Development and License Agreement with Yuva Biosciences on August 27, 2026. The Amendment formalizes a three-phase AI development program and a three-phase Expansion Program to advance all four AI-discovered compounds toward lead compound nomination, updates IP and field-of-use terms, and revises related financial terms.
• Separately, on August 31, 2026 the company filed a Certificate of Amendment to its Articles of Incorporation to increase authorized shares to 1,500,000,000 (1,000,000,000 common; 500,000,000 preferred). The Amendment was approved by holders representing 60.34% of voting power. NorthStrive issued a press release on September 1, 2026 announcing the Amendment.

Key Details

• Amendment date: August 27, 2026; original agreement dated April 9, 2025.
• AI program scope: three-phase AI Development Program (Phases I–III) plus a three-phase Expansion Program to develop biologically validated compounds.
• Compounds: up to four AI-identified compounds to be advanced; “AI Results” defined as the final list of up to four compounds showing biological activity in upregulating ANT, plus raw data.
• Authorized shares after amendment: 1,500,000,000 total (1,000,000,000 common; 500,000,000 preferred); approval by 60.34% of voting power (filed August 31, 2026).

Why It Matters

• The license amendment advances PMGC’s drug discovery efforts with YuvaBio’s AI platform (including MitoNova™ and related datasets), clarifies ownership and use of AI results and platform technology, and sets a formal path to validate and nominate lead compounds — important milestones for pipeline progression.
• Increasing authorized shares gives the company flexibility to issue additional stock or preferred shares for financing, strategic deals, or equity incentives; that can enable growth but also creates potential for future dilution depending on issuances. The filing and press release provide investors with the formal terms and timeline for these changes.